13D Filing: Jeffrey Alan Berg and Ntn Buzztime Inc (NYSEMKT:NTN)

Page 5 of 8 – SEC Filing

 

Pursuant
to Rule 13d-2 promulgated under the Securities Exchange Act of 1934, as amended, this Amendment No. 9 to Schedule 13D (this “Amendment
No. 9
”) amends the Schedule 13D originally filed with the United States Securities and Exchange Commission (the “SEC”)
on September 29, 2008 (the “Original Schedule 13D”), as amended by the amendments thereto previously filed
with the SEC on the dates indicated below (the Original Schedule 13D, as amended through and including this Amendment No. 9 are
collectively referred to herein as the “Schedule 13D”):

 

Amendment
No.
  Filing
Date
1   December
19, 2008
2   January
14, 2011
3   January
14, 2011
4   March
7, 2012
5   September
13, 2012
6   December
27, 2012
7   April
21, 2014
8   November
4, 2016

 

The
Schedule 13D relates to the shares of Common Stock (the “Stock”) of NTN Buzztime, Inc. (the “Issuer”)
owned by Matador Capital Partners, L.P. (the “Fund”), BFK Investments LLC (“BFK”), the general
partner of the Fund, and Jeffrey A. Berg, the Managing Member of BFK. The Fund, BFK and Jeffrey A. Berg are collectively referred
to herein as the “Reporting Persons”. Except as specifically amended by this Amendment No. 9, items in the
Schedule 13D are unchanged.

 

This
Amendment No. 9 reports a decrease in the Reporting Persons’ percentage of beneficial ownership of the outstanding shares
of Stock since the date the Reporting Persons’ last filing on Schedule 13D as a result of the Issuer’s issuance of
200,000 shares of Stock in connection with a registered direct offering that the Issuer completed on March 31, 2017 (the “March
2017 Offering
”). None of the Reporting Persons acquired any shares of Stock in the March 2017 Offering.

 

Information
in this Amendment No. 9 with respect to each of the Reporting Persons is given solely by that particular Reporting Person, and
none of the other Reporting Persons has any responsibility for the accuracy or completeness of information with respect to any
other Reporting Person. Capitalized terms used herein that are not defined herein have the meanings ascribed to them in the Schedule
13D.

 

Item
3. Source and Amount of Funds or Other Consideration

 

The
information provided in Item 5 of this Amendment No. 9 is incorporated by reference to this Item 3.

 

Item
3 of the Schedule 13D is hereby amended and supplemented by adding the following at the end thereof:

 

In
November 2016, the Fund purchased 5,620 shares of Stock reported in Item 5 of this Amendment No. 9 using its working capital.
The aggregate purchase price was $40,679.

 

Item
5. Interest in Securities of the Issuer

 

Paragraphs
(a), (b) and (d) of Item 5 of the Schedule 13D are hereby amended by replacing them in their entirety with the following:

 

Follow Eterna Therapeutics Inc. (NYSEMKT:ERNA)